bl22
mAbexperimentalADC
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 1998 (NCT00021983)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- Pseudomonas exotoxin-A
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109352 ↗
Also known as
- bl22
- bl22
- cat-3888
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00924040 | Phase 2 | Feb 1, 2009 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00126646 | Phase 1 | Jun 1, 2005 | MedImmune, National Cancer Institute (NCI) |
| NCT00077493 | Phase 1 | Jan 1, 2004 | Cambridge Antibody Technology, MedImmune, National Cancer Institute (NCI) |
| NCT00074048 | Phase 2 | Oct 1, 2003 | MedImmune, National Cancer Institute (NCI) |
| NCT00024115 | Phase 1 | Sep 13, 2001 | National Cancer Institute (NCI) |
| NCT00021983 | Phase 1 | Dec 1, 1998 | National Cancer Institute (NCI) |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 3 | 2 | 1998 |
| MedImmune | For profit | 3 | 3 | 2 | 2003 |
| Cambridge Antibody Technology | For profit | 1 | 0 | 1 | 2004 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2009 |
4 organizations
Page 1 / 1